Nyxoah S.A.
- NYXH
- NASDAQ
- Medical - Specialties
- Sleep Apnea Therapy
- Hypoglossal Neurostimulation
$0.95
Today −14.05%Quote Oct 19, 2026, 08:00 PM UTC
−25.50%over the last month
Max drawdown −30.2%From 1-month high −30.2%3 months −28.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Nyxoah
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Sector
Healthcare
Industry
Medical - Specialties
Exchange
NASDAQ
Employees
154
Founded
2009
Market value
$41.1M
Quote Oct 19
Resistance
$1.16
21.9% above price
Price vs analyst targets
5 analysts
Lowest target
$2.31Highest target
$7.00
$2.31Highest target
$7.00
- Price $0.95
- Average target $4.08
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 328% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NYXHPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free